当前位置:首页 > 成功案例 > 迈博药业有限公司

迈博药业有限公司


图片.png

迈博药业有限公司是中国领先的生物医药公司,专注于治疗癌症和自身免疫性疾病的新药及生物类似药的研发和生产。
我们致力于透过我们高效的研发体系以及低成本药品生产能力为市场带来高质量且可负担的创新型生物药品,并充分利用自身丰富的研发经验开发多种治疗产品。
我们的泰州药业生产基地有两栋楼宇,每栋占地15,000平方米,存放我们的单抗体生产设施。目前,我们的候选药物管线目前包括9 个单克隆抗体药物,其中3 个为处于III 期临床试验的核心产品:CMAB007(奥马珠单抗)、CMAB009(西妥昔单抗)和CMAB008(英夫利昔单抗)。此外,我们其他两种候选药物CMAB809(曲妥珠单抗)和CMAB819(纳武单抗)已获批准进行临床试验。

Mabpharm Limited is a leading biopharmaceutical company in China, focusing on the research, development and production of new drugs and biosimilar for cancers and autoimmune diseases.
We strive to bring to market high quality and affordable innovative biologics through our efficient R&D system and low-cost pharmaceutical production capability, and develop differentiated therapeutic products by fully utilizing our extensive R&D experience.
Our production site in Taizhou has two buildings of 15,000 square meters each and houses our mAb production facilities. Our pipeline of drug candidates currently consists of nine monoclonal antibody drugs, three of which are our Core Products under phase III clinical trials: CMAB007 (omalizumab), CMAB009 (cetuximab) and CMAB008 (infliximab). In addition, two of our other drug candidates, CMAB809 (trastuzumab) and CMAB819 (nivolumab), have obtained approval for clinical trials.

http://www.mabpharm.cn/sc/about_info.php



0.173158s